Whitman-Walker is excited to announce our participation in MOSAICO, a new HIV vaccine research study. This international study is an effort to develop a safe and effective global HIV vaccine for people at risk of getting HIV.
We already have important HIV prevention tools, like PrEP – the daily pill that prevents HIV, and PEP – a 28-day course of medication that prevents HIV after an exposure to the virus.